Piper Sandler Downgrades Integra Lifesciences to Neutral, Lowers Price Target to $58

Piper Sandler analyst Matthew O'Brien downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Neutral and lowers the price target from $59 to $58.

Benzinga · 01/07/2020 12:53

Piper Sandler analyst Matthew O'Brien downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Neutral and lowers the price target from $59 to $58.